ACP5 and metastasis: Interestingly, the four patients who received chemotherapy at some point before metastasis surgery had significantly lower RUNX2 immunoreactivity than patients who had never been treated with chemotherapy (p = 0.015), while TRAP immunoreactivity was unaffected (Figure 2).